NUVB Nuvation Bio Inc.
Company Analysis
Latest News
🔴 Nuvation Bio is trading 6% down on November 5, 2026, amid broad market and biotech-sector weakness
Nuvation Bio is trading 5.60% down at $4.46 amid a sharp market-wide sell-off and biotech weakness. - The XBI biotech sector is down 5.19%, while major...
Nuvation Bio Beats on Revenue but a Shrinking Patient Pool Raises the Real Question: Can Market Share Alone Fuel Growth?
Shares of Nuvation Bio slid 7.6% to $4.37 the morning after the oncology company posted mixed third-quarter results, with investors zeroing in on a troubling...
🔴 Nuvation Bio is trading 7.6% down in pre-market as investors weigh mixed results and outlook
Nuvation Bio is trading 7.6% lower at $4.37 following its November 4 earnings release, as investors weigh mixed results and outlook. - Revenue reached $44.95...
Nuvation Bio's third quarter 2026 revenue of $45M beat estimates by 31% on IBTROZI growth
Nuvation Bio reported third quarter 2026 total revenue of $45.0 million, significantly outperforming the analyst consensus of $34.4 million due to strong...
🟢 Nuvation Bio is trading 6.6% up in pre-market as major indexes rise
Nuvation Bio is trading at $5.00, up 6.61%, in line with pre-market gains across major indexes. - The S&P 500 was up 0.87%, Nasdaq Composite 0.93%, and Dow...
Nuvation Bio Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Nuvation Bio is projected to report third-quarter consensus revenue of $34.39 million and a loss per share of $0.12, with its current stock price of $4.76...
🟢 Nuvation Bio is trading 5% up in pre-market — catalyst remains unclear
Nuvation Bio is trading at $4.80, up 5.03% in pre-market; no confirmed company-specific announcement explains the rise. - A November 4, 2026, third-quarter...
🔴 Nuvation Bio is trading 5% down today amid broader risk-off sentiment
Nuvation Bio is trading at $4.45, down 5.43%, with broader market weakness the likeliest explanation; no company-specific negative catalyst was confirmed. -...
🟢 Nuvation Bio rises 5.5% — Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Nuvation Bio is trading 5.5% down amid sector and market weakness
Nuvation Bio is trading at $4.49, down 5.47%, with no fresh company-specific catalyst identified for the October 16 decline. - The move is consistent with...
🔴 Nuvation Bio is trading 5% down
Nuvation Bio is trading 5.06% down at $4.88 on October 5, 2026; no clear company-specific announcement explaining the decline was found. - The company’s...
🔴 Nuvation Bio is trading 5% down
Nuvation Bio is trading at $5.28, down 5.13%, with no clear company-specific announcement explaining the October 2 decline. - The latest item on the company...
🟢 Nuvation Bio is trading 5.5% up in pre-market with no clear new catalyst identified
Nuvation Bio is trading 5.54% higher in pre-market at $5.93, versus the September 29 close of $5.62; no clear new catalyst dated September 30 was...
🔴 Nuvation Bio is trading 4.2% down today amid risk-off markets following Iran proposal rejection
Nuvation Bio is trading 4.2% down at $5.50, with broader macro sentiment the likeliest context rather than a confirmed company-driven move. - No new...
🔴 Nuvation Bio is trading 4.18% down today as broader market weakness pressures risk-sensitive stocks
Nuvation Bio is trading 4.18% down now at $5.84 as broader equity weakness pressures risk-sensitive stocks. - U.S. indices are lower on September 23, 2026,...
Nuvation Bio Rises, FDA Approves Ibtrozi Label Showing 4-Year Cancer Benefit
Nuvation Bio received U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application for Ibtrozi (taletrectinib) four months ahead of...
🟢 Nuvation Bio rises 5.1% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Nuvation Bio is trading 5.5% up in pre-market as yields ease after Fed decision
Nuvation Bio is trading 5.5% up at $6.10 after a broad pre-market recovery, likely reflecting improved global risk appetite following the Federal Reserve’s...
🔴 Nuvation Bio falls 4.5% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Nuvation Bio is trading 6.1% down in pre-market amid broader risk-off trading
Nuvation Bio is trading 6.1% down at $5.70, with the decline appearing consistent with broader risk-off trading and no new company-specific catalyst identified...